ImYoo operates a patient-enabled biodiscovery platform focused on immune dynamics. The company facilitates patient-centric studies by enabling at-home self-collection of small blood volumes for high-resolution single-cell genomics assays. This approach aims to uncover molecular signals to guide precision diagnosis and therapeutic strategies for complex diseases like Lupus.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IAFounders
Product
Problem
Current methods for collecting patient data are often limited to clinical settings, resulting in infrequent and potentially biased snapshots of an individual's health. This lack of continuous, real-world data hinders the ability to understand the dynamic nature of diseases and develop more precise and targeted treatments.
Solution
ImYoo is developing a patient-enabled biodiscovery platform that facilitates longitudinal collection and analysis of patient data. The platform allows individuals to self-collect small blood samples at home using easy-to-use kits, enabling frequent and convenient repeat sampling. These samples are then processed using single-cell RNA sequencing to generate high-resolution immune profiles. ImYoo leverages machine learning models trained on a database of immune profiles to analyze the complex single-cell RNA sequencing data. This approach aims to capture relevant health events as they happen, understand the complexities of diseases, and ultimately enable precision diagnostics and therapies.
Target Audience
ImYoo serves both patients interested in participating in research and researchers seeking access to unique patient data for biomarker discovery, individual baselining, and patient stratification.
Features
- At-home blood self-collection kits for convenient and painless sample acquisition
- Single-cell RNA sequencing to generate high-resolution immune profiles
- Longitudinal data collection to capture changes in an individual's biology over time
- Machine learning models for analyzing complex single-cell RNA sequencing data
- Capability to identify critical biomarkers during key disease events, such as autoimmune flares
- Personalized reports on RNA and cell numbers compared to others in the database (opt-in)
- End-to-end workflow from sample collection to data analysis